Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiogenHAM:IDP +0.12%68 EV-to-EBIT is 28.88 as of Aug. 01, 2026, which is 142% above its 10-year median of 11.93. GuruFocus rates HAM:IDP with a GF Score™ of 68/100 and a GF Value™ of €169.21 (Fairly Valued). The stock has 9 warning signs investors should review. Among 692 Drug Manufacturers companies, Biogen ranks worse than 74.28% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Biogen's Enterprise Value is €32,159 Mil.
Biogen's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €1,114 Mil. Therefore, Biogen's EV-to-EBIT for today is 28.88.
The historical rank and industry rank for Biogen's EV-to-EBIT or its related term are showing as below:
HAM:IDP'
s EV-to-EBIT Range Over the Past 10 Years
Min: 6.06 Med: 11.93 Max: 30.25
Current: 28.59
During the past 13 years, the highest EV-to-EBIT of Biogen was 30.25. The lowest was 6.06. And the median was 11.93.
HAM:IDP's EV-to-EBIT is ranked worse than 74.28% of 692
companies
in the Drug Manufacturers industry
Industry Median: 15.77
vs HAM:IDP: 28.59
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Biogen's Enterprise Value for the quarter that ended in Jun. 2026 was €34,031 Mil.
Biogen's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,114 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen EV-to-EBIT Related Terms
Biogen EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Biogen's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Biogen's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogen's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Biogen's EV-to-EBIT falls into.
Biogen's current Enterprise Value is €32,159 Mil.
Biogen's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,114 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen (HAM:IDP) has a EV-to-EBIT of 28.88 as of Aug. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biogen and its competitors. This is 142% above median its historical median of 11.93. Over the past decade, Biogen's EV-to-EBIT has ranged from 6.06 to 30.25. According to the industry distribution chart, Biogen ranks #514 out of 692 companies in the Drug Manufacturers industry, placing it in the top 74.3%.
Is Biogen's EV-to-EBIT too high?
Biogen's current EV-to-EBIT of 28.88 is 142% above median its 10-year median of 11.93. Over the past 10 years, this metric has ranged from a low of 6.06 to a high of 30.25. The Drug Manufacturers industry median EV-to-EBIT is 15.77. Biogen's value of 28.88 is 83.1% above this industry median. Based on the distribution chart, Biogen ranks #514 out of 692 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Biogen has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's EV-to-EBIT compare to OGN and AMRN?
According to the Drug Manufacturers industry distribution chart, Biogen ranks #514 out of 692 companies for EV-to-EBIT. This places Biogen in the lower half of its industry. The industry median EV-to-EBIT is 15.77. Biogen's value of 28.88 is 83.1% above this benchmark. Historically, Biogen's own EV-to-EBIT has ranged from 6.06 to 30.25 over the past decade. While the company's 10-year median is 11.93 vs. the industry median of 15.77, Biogen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.77, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogen's current EV-to-EBIT of 28.88 is 83.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biogen and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogen's current EV-to-EBIT is 28.88, which is 142% above median its own 10-year median of 11.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (HAM:IDP) is currently considered Fairly Valued. The stock's GF Value™ is €169.21, compared to a current price of €177.08 — trading 4.7% above its estimated fair value. The current EV-to-EBIT is 28.88, which is 142% above median its 10-year median of 11.93 and 83.1% above the Drug Manufacturers industry median of 15.77. Biogen's overall GF Score™ is 68/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Biogen (HAM:IDP), the current EV-to-EBIT is 28.88 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogen (HAM:IDP) Overvalued in 2026?
Based on GuruFocus' analysis, Biogen stock appears to be overvalued.
The current stock price of €177.08 is trading 4.7% above its estimated GF Value™ of €169.21.
GuruFocus considers Biogen to be Fairly Valued.
Key valuation signals for HAM:IDP:
EV-to-EBIT: 28.88 (142% above median its 10-year median of 11.93)
GF Value™: €169.21 vs. price of €177.08 (4.7% above fair value)
Industry Position: 83.1% above the Drug Manufacturers median (#514 of 692)
No single metric tells the full story. See the HAM:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
68GF Score
Get the complete analysis for HAM:IDP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IDP has been successfully added to your 
